Clinical trials
Hepatocellular Carcinoma clinical trials
Below are recruiting hepatocellular carcinoma clinical trials, each written for real people, not researchers. We’re tracking 581 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07224750Recruiting
A blood test to find early signs of gastrointestinal cancer
This study is testing a blood-based test to detect unique molecules (called miRNAs) that may signal the presence of several types of gut or digestive system cancers. The goal is to develop a simple screening tool that could catch these cancers earlier.
Duarte, CaliforniaAges 18 years+ - NCT05468359RecruitingPhase 1/Phase 2
Testing four medicines in children and teens with hard-to-treat tumors
This early-phase trial studies how safe and effective a combination of four medicines is for children and teens with certain solid tumors that have come back or cannot be controlled with standard treatment. It may help by improving tumor control, while also carefully tracking side effects.
Germantown, TennesseeAges Up to 30 years - NCT07557225Recruiting
New PET Scan for Detecting Multiple Cancer Types
This study tests a new type of PET scan (a specialized imaging test) that may better detect certain cancers by looking for a specific marker found on many tumor types. The scan uses a new tracer called 18F-T2 to help doctors see cancer more clearly.
Beijing, Beijing MunicipalityAges 18 years+ - NCT05824975RecruitingPhase 1/Phase 2
Test drug GI-102 alone or with cancer medicines
This Phase 1/2 study tests whether GI-102 is safe and can help shrink advanced solid tumors. It also looks at GI-102 used with standard cancer treatments like pembrolizumab or trastuzumab deruxtecan (T-DXd).
Scottsdale, ArizonaAges 18 years+ - NCT07148050RecruitingPhase 1
CAR T-cell therapy for children with solid tumors
This trial tests a new kind of immunotherapy for children and teens with solid tumors that have not responded to standard treatments. The therapy uses specially engineered T cells (CAR T cells) that target a protein called GPC3 found on many tumor cells, and it includes extra signals (IL-15 and IL-21) to help the T cells work better.
Seattle, WashingtonAges 1–26 - NCT07070518RecruitingPhase 1/Phase 2
Study of GV20-0251 for advanced solid tumors
This trial tests a new study drug, GV20-0251, for people with advanced solid tumors that no longer respond to standard therapies. It aims to see if the drug can shrink tumors or slow their growth.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06422403RecruitingPhase 2
Study on giving immunotherapy less often for advanced cancer
This trial tests whether giving certain immunotherapy drugs less often than usual is safe and still works well for people with advanced stomach, liver, or lung cancer. It might mean fewer hospital visits while still controlling the cancer.
SingaporeAges 21–99 - NCT07760012Recruiting
Pet scan with new tracer for solid tumors
This study uses a new imaging tracer, called 68Ga-SorB, during a PET/CT scan to look at tumors. It may help doctors see cancer more clearly. The trial is for adults with certain types of solid tumors (such as melanoma, liver, lung, breast, pancreatic, ovarian, or bile duct cancer) who need a PET/CT scan as part of their care.
Beijing, Beijing MunicipalityAges 18 years+ - NCT03686709Recruiting
Extra scan and blood testing with Y90 radioembolization
This study looks at how well Y90 “radioembolization” treatment delivers radiation and how much radiation reaches your body. If you can safely get extra PET/CT scans and blood tests around your treatment, you may be invited to participate.
Knoxville, TennesseeAges 18 years+ - NCT04371042Recruiting
Study of liver disease and genes in people with fatty liver
This study collects information about metabolic and unexplained (cryptogenic) liver disease and looks at “omics” tests, which are lab tests that measure patterns in blood or tissue to learn what drives the disease. It may help researchers better understand fatty liver and related serious complications, like liver scarring and liver cancer.
Roma, Rome/lazio/italyAges 18 years+ - NCT04777942Recruiting
New liver cancer treatment plan for high-risk early-stage patients
This trial studies a treatment approach (a combination given through the liver) for people with early liver cancer that can be surgically removed but has a high chance of coming back. It may help reduce the risk of recurrence after treatment.
Guangzhou, GuangdongAges 18–75 - NCT04455932Recruiting
Test shorter MRI versus ultrasound for liver cancer screening
This study compares a shorter, non-contrast MRI and ultrasound to monitor for liver cancer in people with cirrhosis whose ultrasound images aren’t clear enough. It aims to see which method works better and may help you get safer, more reliable follow-up.
Camperdown, New South WalesAges 20–85 - NCT04946773Recruiting
Deep liver testing study for cancer and non-cancer liver disease
This study looks closely at how the liver’s immune system and disease processes work in people with liver problems, including some with suspected or confirmed liver/bile duct cancer. You may also be offered a liver needle sample (FNA) if it’s safe for you.
Oxford, OxfordshireAges 18–75 - NCT05323201RecruitingPhase 1/Phase 2
B7H3 CAR-T therapy for advanced liver cancer
This trial tests an immune therapy made from your own blood cells (CAR-T) to treat advanced, unresectable liver cancer. It’s designed for people whose tumor has a specific marker called B7H3 and who meet blood, organ, and safety requirements.
Xuzhou, JiangsuAges 18–70 - NCT05466565Recruiting
Peginterferon antiviral treatment after liver cancer surgery
This trial studies an antiviral medicine given after surgery for liver cancer to help prevent the cancer from coming back. It focuses on people who are hepatitis B–positive (HBsAg positive) and have complete remission on follow-up checks.
Changsha, HunanAges 18–65 - NCT05276037Recruiting
PET/CT scan to guide liver transplant decisions in liver cancer
This trial studies how a whole-body PET/CT scan using a “tracer” called 18F-FDG can help decide which people with liver cancer (HCC) may benefit from a liver transplant. It may help the transplant team better sort out who is likely to do well after transplant.
AntwerpAges 18–80 - NCT05534906Recruiting
Detecting very early liver cancer and tracking its natural course
This study looks at how well doctors can detect small, early liver cancer and then follow how it changes over time. It may help your care team choose the best next steps based on earlier, clearer detection.
Oxford, OxfordshireAges 18–100 - NCT05541601Recruiting
Study to detect liver cancer early in people with cirrhosis
This study follows people with cirrhosis to see how best to detect liver cancer early. If you qualify, you may receive regular monitoring that could help find liver cancer sooner, when treatment is more likely to work.
Oxford, OxfordshireAges 18–100 - NCT05608213RecruitingPhase 3
Lenvatinib plus radiation seeds vs lenvatinib alone for liver cancer
This Phase 3 trial compares lenvatinib plus implanted radiation seeds versus lenvatinib alone in people with liver cancer that no longer responds to TACE. It aims to improve how long patients can control the cancer inside the liver.
Guangzhou, GuangdongAges 18–75 - NCT05331911RecruitingPhase 4
Propofol anesthesia vs sevoflurane for liver tumor surgery
This study compares two types of general anesthesia—propofol-based total intravenous anesthesia versus sevoflurane inhaled anesthesia—during planned surgery to remove liver tumors. The goal is to see whether the anesthesia choice affects long-term outcomes after partial liver removal for hepatocellular carcinoma.
Kaohsiung CityAges 20–80 - NCT05476432RecruitingPhase 3
One-day versus two-day chemotherapy for unresectable liver cancer
This study compares two schedules of chemotherapy to treat liver cancer that cannot be removed with surgery. It aims to see whether the shorter schedule works about as well, with similar safety.
Foshan, GuangdongAges 18–75 - NCT04442334Recruiting
European registry for people with fatty liver
This registry collects health and lifestyle information from adults with suspected or confirmed fatty liver (NAFLD) to help researchers better understand the condition. You may be asked about diet, exercise, alcohol intake, and some liver-related tests.
AntwerpAges 18–100 - NCT05718492Recruiting
Tested HAIC for liver cancer after prior immunotherapy
This trial studies HAIC, a type of targeted treatment delivered into the liver, for advanced hepatocellular carcinoma (liver cancer) that has already been treated with immune and anti-blood-vessel therapies. It aims to see whether HAIC can help control the cancer safely after those earlier treatments.
Guangzhou, GuangdongAges 18–75 - NCT05870969Recruiting
Digital monitoring to catch liver cancer risk early
This study tests a digital (computer/phone-based) system to help track people with higher risk of liver cancer so cancers can be found earlier. It may help by guiding regular check-ins and making early diagnosis more efficient.
Shanghai, Shanghai MunicipalityAges 18–75
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for hepatocellular carcinoma?
- Yes. Clin2 currently lists 581 recruiting hepatocellular carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a hepatocellular carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a hepatocellular carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.